O’Dwyer, R.; Junker, S.; Szulkin, R.; Kienzle, S.; Kearney, M.; Sridhar, S.S.
Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey. Cancers 2025, 17, 509.
https://doi.org/10.3390/cancers17030509
AMA Style
O’Dwyer R, Junker S, Szulkin R, Kienzle S, Kearney M, Sridhar SS.
Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey. Cancers. 2025; 17(3):509.
https://doi.org/10.3390/cancers17030509
Chicago/Turabian Style
O’Dwyer, Richard, Sophia Junker, Robert Szulkin, Scarlette Kienzle, Mairead Kearney, and Srikala S. Sridhar.
2025. "Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey" Cancers 17, no. 3: 509.
https://doi.org/10.3390/cancers17030509
APA Style
O’Dwyer, R., Junker, S., Szulkin, R., Kienzle, S., Kearney, M., & Sridhar, S. S.
(2025). Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey. Cancers, 17(3), 509.
https://doi.org/10.3390/cancers17030509